Hyunsoo Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyunsoo Ha has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hongmok Kwon
College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea
2 shared publications - Taehyeong Lim
College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea
2 shared publications - Youngjoo Byun
College of Pharmacy Korea University Sejong Republic of Korea
2 shared publications Bernie Byeonghoon Park
College of Pharmacy, Korea University
1 shared publicationDonghak Kim
Department of Biological Sciences, Konkuk University
1 shared publicationDongju An
Department of Biological Sciences, KAIST
1 shared publication
Latest Publications
- Open Access
- 11 December 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 269-279
TNP and its analogs: Modulation of IP6K and CYP3A4 inhibition
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.
- 11 December 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 37 (1) , 269-279
Open AccessTNP and its analogs: Modulation of IP6K and CYP3A4 inhibition
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.
- 16 April 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (6) , 525-547
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...
- 16 April 2021
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (6) , 525-547
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...